Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07389239 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
A Phase 1 study, sponsored by University of Chicago.
- Not yet
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07389239 is a Phase 1 study that has not yet begun recruiting, run by University of Chicago. The registered enrollment target is 24 participants.
The verdict
NCT07389239, a Phase 1 study, has not yet begun recruiting, sponsored by University of Chicago.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens.
Interventions
- DRUG Decitabine
- DRUG Aldesleukin
- DRUG Cyclophosphamide Conditioning
- BIOLOGICAL NY-ESO-1 TCR/ dnTGFβRII
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-06-23 |
| Est. Completion | 2031-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07389239
The ClinicalTrials.gov registry entry for NCT07389239 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Decitabine is the first listed.
NCT07389239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07389239 about?
NCT07389239 is a clinical study titled "A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.". This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens.
What is the current status of trial NCT07389239?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-06-23. Estimated completion is 2031-12-10.
What interventions are being tested in trial NCT07389239?
The interventions under investigation include: Decitabine (DRUG), Aldesleukin (DRUG), Cyclophosphamide Conditioning (DRUG), NY-ESO-1 TCR/ dnTGFβRII (BIOLOGICAL).
Who is sponsoring clinical trial NCT07389239?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.